About Heterogeneous nuclear ribonucleoprotein C-like 4
Heterogeneous nuclear ribonucleoprotein C-like 4 (HNRNPCL4) is a protein
from Homo sapiens identified by UniProt accession
P0DMR1, 293 residues long.
MolForge cross-references it against 0 known binders and
11 disease associations.
Target properties
| Protein name | Heterogeneous nuclear ribonucleoprotein C-like 4 |
| UniProt accession | P0DMR1 |
| Gene | HNRNPCL4 |
| Organism | Homo sapiens |
| Length | 293 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (11)
Diseases linked to this target (Open Targets).
- MODY · score 0.05
- hereditary hyperferritinemia with congenital cataracts · score 0.04
- Juvenile cataract - microcornea - renal glucosuria · score 0.04
- juvenile cataract-microcornea-renal glucosuria syndrome · score 0.04
- islet cell adenomatosis · score 0.04
- Familial ocular anterior segment mesenchymal dysgenesis · score 0.04
- exfoliation syndrome · score 0.03
- granular corneal dystrophy type I · score 0.03
- Cataract with Y-shaped suture opacities · score 0.03
- Cataract-microcornea syndrome · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P0DMR1-F1 | alphafold | PREDICTED | 70.52 | — |
Amino-acid sequence (293 residues)
MASNVTNKMD PHSMNSRVFI GNLNTLVVKK SDVEAIFSKY GKIAGCSVHK GFAFVQYDKE KNARAAVAGE DGRMIASQVV DINLAAEPKV NRGNAGVKRS AAEMYGSSFD LDYNLQRDYY GGMYSFPARV PPPPPIALAV VPSKRQRISG NTSRRGKSGF NSKSGKRGSS KSGKLKGDDL QAIKQELTQI KQKVDSLLEN LEKIEKEHCK QGVEVKNAKS EEEQTSSSSK KDKTHVKMES EGGADDSVEE GDLLCDDDNE DQGDNQLELI KDDEKGAEEG EDDRDRANGQ DDS
Explore Heterogeneous nuclear ribonucleoprotein C-like 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets